International
Original antifibrotic product for combined therapy of connective tissue hyperplasia diseases (adhesions, cicatricial and fibrotic processes).
Therapeutic areas: gynecology, urology, dermatology and venereology, pulmonology and phthisiology, surgery, esthetic medicine, and rheumatology.
Dosage forms: suppositories, and lyophilizate for preparation of solution for injection.
*The World Health Organization (WHO) assigned an international nonproprietary name (INN) to the Russian product Longidaza® in 2015.